Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook - Merck & Co (NYSE:MRK) : vimarsana.com

Merck reported Q1 sales of $15.8 billion, beating estimates, with cancer drug Keytruda driving growth. Company raised full-year revenue and EPS forecasts.

Related Keywords

Merck Januvia , Merck Co Inc , , Sotatercept For Rare Lung , Harpoon Therapeutics , Most Important Catalyst For Merck ,